Stock Monitor: RXi Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 25, 2018 / Active-Investors.com has just released a free research report on Codexis, Inc. (NASDAQ: CDXS). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CDXS as the Company's latest news hit the wire. On April 23, 2018, the Company announced that it has entered into a strategic collaboration with Porton Pharma Solutions ("Porton") to deploy Codexis' world-leading biocatalyst technology within Porton's global custom intermediate and active pharmaceutical ingredients (API) development and manufacturing business. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for RXi Pharmaceuticals Corporation (NASDAQ: RXII), which also belongs to the Healthcare sector as the Company Codexis. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=RXII

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Codexis most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=CDXS

Terms of the Collaboration

  • Codexis will license core elements of its biocatalyst technologies to Porton, including its proprietary biocatalyst libraries, high-throughput screening, and enzyme manufacturing know-how;

  • Codexis will also provide preferential access to its CodeEvolver® protein engineering platform technology for the creation of new biocatalytic process solutions;

  • Porton will install new operations to drive adoption and optimal application of these biocatalyst technologies into its custom contract development and manufacturing (CDMO) offerings to pharmaceutical customers.

Strategic Benefits of the Collaboration

The partnership will accelerate the creation and commercialization of new, low-cost, sustainable manufacturing processes, exploiting the benefits of biocatalysts to a growing number of the world's small molecule pharmaceuticals. The partnership reinforces the benefits of reduced costs, enhanced sustainability and improved product quality that biocatalysts can deliver to the manufacturing of the world's small molecule pharmaceuticals.

Biocatalysis is the Most Impactful Technology to Improve the Future of Pharmaceutical Manufacturing

Oliver Ju, Chairman and CEO at Porton Pharma Solutions, stated that technological leadership is central to the Company's strategy to grow and deliver value to its pharmaceutical clients around the globe.

Oliver added that the Company believes that biocatalysis is the most impactful technology to improve the future of pharmaceutical manufacturing, and there is not a more capable player to partner with than Codexis.

Partnership will Enable Codexis to Reach a Greater Share of the World's Pharmaceutical Manufacturing Market

John Nicols, President and Chief Executive Officer of Codexis, stated that the Company is delighted to establish this unique partnership with Porton.

John added that given Porton's significant and fast-growing presence as a leading global CDMO, the Company will now be able to reach a greater share of the world's pharmaceutical manufacturing market.

Codexis and Nestlé Health Science Entered into Healthcare-Focused Protein Engineering Platform Partnership

In October 2017, Codexis and Nestlé Health Science announced a strategic collaboration encompassing multiple projects accessing Codexis' CodeEvolver® protein engineering platform. The collaboration included an option for the global development of Codexis' novel, orally delivered, enzyme, CDX-6114, for the management of phenylketonuria (PKU), an orphan metabolic disorder. Additionally, Nestlé Health Science secured strategic access to the CodeEvolver® protein engineering platform for the discovery of biotherapeutics for other metabolic disorders, and for the development of novel enzyme products for Nestlé Health Science's Medical Nutrition and Consumer Care business areas.

About Codexis, Inc.

Founded in 2002 and headquartered in Redwood City, California, Codexis is a leading protein engineering company that applies its technology to the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals.

About Porton Pharma Solutions Ltd

Founded in 2005, Porton Pharma Solutions is a top-tier, China-based external manufacturing partner and strategic supplier of custom drug intermediates and Active Pharmaceutical Ingredients (APIs) to many of the world's leading pharmaceutical companies.

Stock Performance Snapshot

April 24, 2018 - At Tuesday's closing bell, Codexis' stock advanced 4.00%, ending the trading session at $11.70.

Volume traded for the day: 447.95 thousand shares, which was above the 3-month average volume of 392.44 thousand shares.

Stock performance in the last month ? up 6.36%; previous three-month period ? up 38.87%; past twelve-month period ? up 168.97%; and year-to-date - up 40.12%

After yesterday's close, Codexis' market cap was at $623.49 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors